Full Logo - OKYO .jpg
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
30 oct. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
Full Logo - OKYO .jpg
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
23 oct. 2024 07h00 HE | OKYO Pharma LTD
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled,...
Full Logo - OKYO .jpg
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
16 oct. 2024 07h00 HE | OKYO Pharma LTD
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The...
Full Logo - OKYO .jpg
OKYO Pharma Announces Chairman Acquires Shares
10 sept. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces Chairman Acquires Shares
05 sept. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma CEO Interview to Air on Bloomberg TV
23 août 2024 09h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces Chairman Acquires Shares
23 août 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces Chairman Acquires Shares
21 août 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
06 août 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09 févr. 2024 07h00 HE | OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...